LYPLAL1 and type 2 diabetes mellitus: Apart from the previous study delineating that LYPLAL1-DT exerted protective effects to human umbilical vein endothelial cells (HUVECs) in type 2 diabetes with macrovascular complication via mediation of the miR-204-5p/SIRT1 axis [26], LYPLAL1-DT has not hitherto been explored in cancers.